Show simple item record

dc.contributor.authorKnockaert, Mirjam
dc.contributor.authorManigart, Sophie
dc.contributor.authorCattoir, Sofie
dc.contributor.authorVerstraete, Willy
dc.date.accessioned2017-12-02T14:53:25Z
dc.date.available2017-12-02T14:53:25Z
dc.date.issued2015
dc.identifier.doi10.1016/j.btre.2015.01.002
dc.identifier.urihttp://hdl.handle.net/20.500.12127/5294
dc.description.abstractThree distinct fields of gene manipulated biotechnology have so far been economically exploited: medical biotechnology, plant biotechnology and industrial biotechnology. This article analyzes the economic evolution and its drivers in the three fields over the past decades, highlighting strong divergences. Product and market characteristics, affecting firms' financing options, are shown to be important enablers or inhibitors. Subsequently, the lack of commercialization in a fourth type of gene manipulated biotechnology, namely environmental biotechnology, is explained by the existence of strong barriers. Given the latter's great promises for environmental sustainability, we argue for a need to push the commercial valorization of environmental biotechnology. Our research has strong implications for (technology) management research in biotechnology, pointing to a need to control for and/or distinguish between different biotechnology fields.
dc.language.isoen
dc.subjectAccounting & Finance
dc.titleA perspective on the economic valorization of gene manipulated biotechnology: Past and future
dc.identifier.journalBiotechnology Reports
dc.source.volume6
dc.source.issueJune
dc.source.beginpage56
dc.source.endpage60
vlerick.knowledgedomainAccounting & Finance
vlerick.typearticleJournal article
vlerick.vlerickdepartmentA&F
dc.identifier.vperid207760
dc.identifier.vperid35880
dc.identifier.vperid35884
dc.identifier.vperid80915
dc.identifier.vpubid6547


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record